ANZCTR search results

Firstly, this project will investigate the number of people in South Australia who experience difficulties after sustaining a concussion/mild traumatic brain injury following a vehicular accident. In addition, these individuals will be provided assessment and intervention according to best practice guidelines and changes over time will be recorded. In addition, costs for the service will be evaluated and cost drivers determined. This analysis will then let us understand whether the early intervention is effective in preventing long term sequelae, in particular recognising and managing frontal lobe injury syndromes, and evaluating whether the costs incurred are worthwhile.

The purpose of this study is to determine whether a cream (Sirolimus) is both safe and effective in reducing the burden of skin cancer in transplant recipients. Who is it for? You may be eligible for this study if you are an adult who has received a solid organ transplant more than 12 months ago, and have been affected by many BCCs or SCCs. Study details All participants will apply the Sirolimus cream to one forearm and the placebo cream to the other forearm but they will not know the difference between each cream. Creams will be applied every night for 12 weeks. Participants in this study will be followed up over 24 weeks to assess for any changes in skin lesions via photographs, skin biopsies and blood tests. It is hoped that this research will help determine whether Sirolimus can be effective at preventing skin cancers in transplant recipients.

The study aims to reduce circulating blood lipids (fats) and inflammation, two key modifiable risk factors of dyslipidaemia; a major contributor to heart disease. Plant sterols and curcumin are potent cholesterol-lowering and anti-inflammatory agents, respectively. We have previously investigated this novel combination as dietary supplements and now pose the development of a functional food containing both ingredients. We hypothesis that the functional food containing plant sterols and curcumin will be an effective delivery mode for both bioactives, have enhanced compliance and be effective for lowering circulating blood lipids and inflammatory markers in individuals with high cholesterol.

The aim of this study is to establish a comprehensive clinical registry for patients with brain tumours in Australia. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with a brain tumour. Study details Participants in this study will continue to receive routine clinical care, which will not be impacted by involvement in this study. All enrolled patients will have clinical data collected for up to 5 years. Data captured will include presentation and the disease course of brain tumours, surgical interventions, prescription of system therapies, and information regarding multi-disciplinary management and outcomes of this disease in the routine clinical practice setting. This registry will help to describe the current practice patterns and identify any deficiencies or abnormalities. By doing so, we can ensure that Australian brain tumour patients receive the best care possible.

Obesity and related cardiometabolic diseases represents an escalating global health challenge, requiring new therapeutic targets. Mineralocorticoid receptors (MRs) are hormone receptors present on fat cells, in high abundance in obese subjects. In animals, blocking the MRs by a tablet called spironolactone protects against obesity and diabetes over time. This project will investigate whether spironolactone provides long-term metabolic benefits in humans. Thirty-two young overweight/obese subjects will be recruited. Half will be randomly assigned to a 16-week treatment with spironolactone and the other half to placebo (medication-free tablet). Assessments including body-composition scan, nuclear imaging using a glucose tracer, calorimetry, blood tests, abdominal fat sampling will be undertaken before and after treatment to determine whether spironolactone improves body fat mass, tissues glucose uptake and function of fat cells. The results will help determine the novel therapeutic potential of MR blockade for management of obesity and metabolic diseases

This is an open-label, outpatient, multiple ascending dose study of AB-2004 in approximately 35 adolescent subjects diagnosed with ASD accompanied by gastrointestinal symptoms. The primary outcome is to assess the safety and tolerability of AB-2004 administered daily over a period of 8 weeks as assessed by the frequency and severity of adverse events and laboratory abnormalities. Secondary outcomes include assessments of the effects of AB-2004 on intestinal permeability, systemic levels of host and microbially derived metabolites, biomarkers of systemic inflammation, the fecal microbiome profile, gastrointestinal signs and symptoms, core behaviors and affect (particularly anxiety and irritability) and the measures of brain connectivity and white matter integrity.

The purpose of this study is to assessment the safety and tolerability of a new medication called FPT155. Who is it for? You may be eligible for this study if you are aged 18 or older and have a solid tumour. Study details All participants will be treated with a different amount of FPT155. This medication is administered through a needle in the arm once every 21 days for every 3 weeks .As part of this study, all participants will have a number blood tests, Hematology, Clinical chemistry, Coagulation, Urinalysis. It is hoped this research will demonstrate the safety and tolerability of this new medication and provide important does-related information for future studies.

There are currently no objective ways to diagnose migraine and there is no way to determine what underpins the origins of migraine in each individual. This leaves doctors and migraine sufferers without the key information that would allow for optimal treatment selection and specific diagnosis. What is needed is a simple test that can diagnose migraine patients from people without migraine and can guide treatment selection. This study will therefore explore whether some new technologies may be useful as a blood test(s) to diagnose migraine.

BIOMONITOR III First In Man Study aims to collect first implantation experience with a new generation of implantable cardiac monitors. BIOMONITOR III is a miniaturised version of its predecessor BIOMONITOR II which has sought to address the issue of increasing patient comfort with a smaller device, but still having all of the same diagnostic capability as BIOMONITOR II. The objective thus is to examine the ease of implant of the device by physicians, and to assess its full diagnostic capacity on patients.

People with interstitial lung disease often have poor quality of life because of distressing breathlessness and reduced exercise tolerance. Their survival is often poor and there are limited medical treatments available. There is no proven treatment for relieving symptoms in patients with these conditions. Handheld fans have been shown to be a useful intervention for breathlessness in patients with other lung conditions and cancers. This study aims to explore the use of a handheld fan, a simple and easily portable device, for symptom management in people with interstitial lung disease.